XML 80 R67.htm IDEA: XBRL DOCUMENT
v3.26.1

Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended
--- | --- | ---
Jan. 31, 2025 | Mar. 31, 2026 | Mar. 31, 2025
Lessee, Lease, Description [Line Items] |  |  |
Payments to acquire intangible assets |  | $ 0 | $ 10
Consideration paid |  | 895 | $ 5
National Institute of Allergy and Infectious Diseases member |  |  |
Lessee, Lease, Description [Line Items] |  |  |
Payments to acquire intangible assets | $ 10 |  |
Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) |  |  |
Lessee, Lease, Description [Line Items] |  |  |
Amount awarded to other party |  | $ 878 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details
Name: | us-gaap_LesseeLeaseDescriptionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mrna_NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrna_ArbutusBiopharmaCorporationArbutusAndGenevantSciencesGmbHGenevantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |